Amniotic fluid beta-endorphin: a prognostic marker for gastroschisis?

Area of Science:

• Perinatal medicine
• Fetal surgery
• Neonatal care

Background:

• Gastroschisis is a congenital defect with significant postnatal morbidity.
• Predictive markers for gastroschisis severity are crucial for optimal management.
• Amniotic fluid beta-endorphin (AFBE) has been investigated as a potential biomarker.

Purpose of the Study:

• To evaluate amniotic fluid beta-endorphin (AFBE) as a predictor of postnatal morbidity in fetuses diagnosed with gastroschisis.
• To establish a correlation between AFBE levels and the severity of gastroschisis complications.

Main Methods:

• Assay of beta-endorphin in amniotic fluid samples from pregnant women with fetal gastroschisis and controls.
• Comparison of AFBE levels between gastroschisis cases and controls.
• Investigation of the relationship between peak AFBE values and postnatal morbidity markers.

Main Results:

• Elevated AFBE levels (above 10 microg/L) were observed in a subset of gastroschisis cases.
• Higher postnatal morbidity, including longer durations of mechanical ventilation, parenteral feeding, and hospitalization, was significantly associated with peak AFBE levels exceeding 10 microg/L.
• No significant association was found between AFBE levels and prenatal fetal bowel dilation.

Conclusions:

• High amniotic fluid beta-endorphin (AFBE) levels are associated with more severe cases of gastroschisis.
• Elevated AFBE may reflect fetal stress or pain resulting from prenatal intestinal damage.
• AFBE shows potential as a predictive biomarker for postnatal outcomes in gastroschisis.